Skip to content
Search

Latest Stories

Pharmacy First needs proper support to reach its full potential: Numark

Pharmacy First: Workforce capacity continues to be a concern
Community pharmacies in England delivered 2 million Pharmacy First consultations in the first year alone (gettyimages)

Sector needs a remuneration model that ensures pharmacies are not just delivering Pharmacy First service, but thriving while doing so 

Pharmacy First has demonstrated the enormous value of community pharmacy in providing accessible front-line care. However, pharmacists continue to face several challenges in delivering the service.

“Pharmacy First is a success, but it needs proper support to reach its full potential,” said Numark chairman Harry McQuillan.


In the first year alone, community pharmacies in England delivered an incredible 2 million consultations, highlighting the vital role pharmacists and their teams play in supporting the NHS.

“This significant number shows the high demand for accessible healthcare and the trust patients place in their local pharmacy teams. It’s clear that when empowered, community pharmacy delivers,” McQuillan told Pharmacy Business.

Key challenges in providing the service

While Numark members have embraced Pharmacy First, McQuillan pointed out several challenges that persist:

“Workforce capacity continues to be a concern, with patient demand sometimes outpacing available resources.

“The administrative burden, particularly around IT interoperability, data capture, and reimbursement processes, adds complexity.”

“Additionally, some geographical areas are still struggling with public awareness, meaning more work is needed to ensure patients understand when and how they can access Pharmacy First.”

Lessons learned over the past year

One key lesson is that “when community pharmacy is empowered, it delivers,” McQuillan said.

Pharmacy First has proven that pharmacists can effectively manage common clinical conditions and free up GP capacity.

However, McQuillan stressed the need for greater investment in workforce and digital solutions to scale the service and “clearer patient pathways and a more joined-up approach across primary care” to ensure pharmacists can work at the top of their clinical skillset.

Appropriate remuneration is essential

Although Pharmacy First represents a positive shift in recognising the clinical role of pharmacists, concerns remain about whether funding levels are sufficient to make the service sustainable long-term.

McQuillan stated that the current reimbursement model does not “fully reflect the time, expertise, and infrastructure required to deliver high-quality consultationsfor many contractors.

“Future funding must ensure that pharmacies are not just delivering the service but thriving while doing so,” he noted.

According to him, one way to achieve this is by designing a remuneration model that ensures “the entire funding allocated for the Pharmacy First service flows to the network."

“Community pharmacy has the clinical expertise to do more, and to unlock its full potential, appropriate remuneration is essential,” McQuillan reiterated.

“Funding must reflect the complexity of consultations and ensure that pharmacies are incentivised to continue delivering and expanding this vital service,” he added.

Enhancing the service: Improvements needed

To strengthen Pharmacy First, McQuillan has recommended several key improvements:

  • Streamlined digital integration between pharmacy and GP systems to reduce duplication and ensure seamless referrals and record-keeping.
  • Sustainable funding to properly resource the service for the long term.
  • Expansion of conditions and treatments available through Pharmacy First, enabling pharmacists to manage more patients without the need for GP intervention.
  • A coordinated national public awareness campaign to ensure people know they can turn to their local pharmacy for expert advice and treatment

Drawing from his experience in Scotland, McQuillan emphasised that the best marketing campaign is for the community pharmacy network to engage with the service and deliver an experience that encourages patients to return the next time they have symptoms of a common clinical condition.

Numark’s key asks for policymakers

To improve the Pharmacy First scheme going forward, Numark has called on policymakers to:

  • Increase investment in digital interoperability to ensure pharmacy teams can seamlessly share and access patient information.
  • Review funding models to fairly reflect the workload and professional expertise involved and delivers the intended full value to the network.
  • Expand the range of conditions that can be treated under Pharmacy First
  • Implement a citizen-led approach, making the service accessible to all without requiring referrals from other healthcare professionals.

McQuillan believes that greater public awareness campaigns, backed by government, would drive more appropriate use of the service, further reducing NHS pressures.

 

 

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less